ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1584

The Use of a Visual Four-Score Scale Improves the Yield of 18F-FDG PET-CT Imaging in the Diagnosis of Cyst Infection in Patients with Autosomal Dominant Polycystic Kidney Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic


  • Jouret, Francois, Universite de Liege, Liege, Belgium
  • Neuville, Marie, Universite de Liege, Liege, Belgium
  • Lovinfosse, Pierre, Universite de Liege, Liege, Belgium
  • Jadoul, Alexandre, Universite de Liege, Liege, Belgium
  • Thys, Marie, Universite de Liege, Liege, Belgium
  • Seidel, Laurence, Universite de Liege, Liege, Belgium
  • Hustinx, Roland, Universite de Liege, Liege, Belgium

[18F]FDG PET/CT proved useful in the diagnosis of renal and hepatic cyst infection (CyI) in patients with autosomal dominant polycystic kidney disease (ADPKD). However, the definition of CyI by [18F]FDG PET/CT is subjective. Here, we infer a diagnostic threshold of [18F]FDG uptake in case of CyI based on a visual 4-point scale.


All ADPKD patients who were hospitalized between January 2007 and March 2019 for suspected CyI and who underwent an [18F]FDG PET/CT were retrospectively identified. CyI was defined upon 5 concomitant criteria: (i) fever ≥38°C; (ii) abdominal pain; (iii) peak plasma C-reactive protein levels ≥70 mg/L; (iv) no other cause of inflammation; and (v) favorable outcomes after antibiotics for ≥21 days. First, all [18F]FDG PET/CT images were qualitatively interpreted by 2 blinded board-certified physicians in nuclear medicine. CyI was diagnosed in case of (i) homogeneous or (ii) heterogeneous [18F]FDG accumulation in cyst wall, or (iii) diffuse [18F]FDG accumulation within the cyst. Next, the uptake of [18F]FDG of the suspected CyI was scored in comparison to blood pool and liver activities. An accumulation of [18F]FDG around the cyst equivalent or inferior to the blood pool was scored as 1. If it was superior to the blood pool but inferior or equal to the hepatic [18F]FDG background, it was scored as 2. If it was slightly superior to the liver, it was scored as 3. If it was largely superior to the hepatic [18F]FDG activity, it was scored as 4.


Sixty [18F]FDG PET/CT (man/woman ratio of 54.1%) were performed for suspected CyI in 38 ADPKD patients: 29 episodes met the gold-standard criteria for CyI. The visual assessment of PET/CT images reached a sensitivity of 73.1% and a specificity of 70.6%. The pattern of [18F]FDG accumulation around or within the suspect cyst was not discriminant. By contrast, the 4-point scale improved the diagnostic yield (specificity of 85.3%), with a diagnostic threshold of [18F]FDG uptake ≥3, i.e. higher than the hepatic background.


[18F]FDG PET-CT imaging helps in the diagnosis of CyI in ADPKD patients, and the use of a 4-point scoring of [18F]FDG uptake improves its yield, with positive and negative predictive values of 78.3% and 78.4% respectively.